Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZSYY001
- Development stage
- Unknown
- Lead developer
- Zhongsheng Pharma
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
ZSYY001 is a novel nanoparticle formulation of polymeric micellar paclitaxel (PM-paclitaxel) designed to improve paclitaxel delivery while avoiding the side effects associated with Cremophor EL, the solvent used in conventional paclitaxel formulations. ZSYY001 utilizes polymeric micelles to solubilize paclitaxel, enabling intravenous administration without the need for premedication. In preclinical studies, ZSYY001 demonstrated significant tumor growth inhibition with minimal toxicity. In a phase I clinical trial in patients with advanced solid tumors, ZSYY001 showed a favorable safety profile, no acute hypersensitivity reactions, and promising antitumor activity, with partial responses and stable disease in several patients, including those previously treated with paclitaxel. Dose escalation up to 390 mg/m^2 did not reach a maximum tolerated dose, and the pharmacokinetic profile was nonlinear.
- Brand names
- TAXUS Liberté-SR
- Other names
- polymeric micellar paclitaxelPM-paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on ZSYY001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZSYY001.